Literature DB >> 10468608

Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells.

F H Engels1, G K Koski, I Bedrosian, S Xu, S Luger, P C Nowell, P A Cohen, B J Czerniecki.   

Abstract

Effective host T lymphocyte sensitization to malignant cells depends on successful antigen presentation. In this study, we examined the capacity of malignant myeloid progenitor cells of patients in the chronic phase of chronic myelogenous leukemia (CML) to acquire characteristics of activated dendritic cells (DCs) after intracellular calcium mobilization, thereby bypassing a need for third-party antigen-presenting cells. Treatment of purified CD33(+) CML cells from 15 patients with calcium ionophore (CI) consistently resulted in de novo expression of the costimulatory molecules CD80 (B7.1) and CD86 (B7.2), CD40 and the DC-specific activation marker CD83, as well as marked up-regulation of MHC class I and II molecules and the adhesion molecule CD54. Most of these changes occurred within 24 hr of treatment. Morphologically, CI-treated CML cells developed long dendritic projections similar to those seen in mature DCs. Functionally, CI-treated CML cells provided stimulation of allogeneic T lymphocytes 10- to 20-fold that of untreated CML cells or untreated monocytes. Fluorescent in situ hybridization of CI-activated CML cells confirmed their leukemic origin by displaying the typical bcr/abl fusion signal. No difference in bcr/abl translocation percentages between untreated and CI-treated CML nuclei was observed. These observations indicate that calcium mobilization may constitute a valuable approach for rapidly and reliably generating CML-derived DCs for immunotherapy of CML.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468608      PMCID: PMC17888          DOI: 10.1073/pnas.96.18.10332

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Indications for marrow transplantation in chronic myelogenous leukemia.

Authors:  E D Thomas; R A Clift
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

2.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

Authors:  H J Kolb; J Mittermüller; C Clemm; E Holler; G Ledderose; G Brehm; M Heim; W Wilmanns
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

3.  HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.

Authors:  S I Mannering; J L McKenzie; D B Fearnley; D N Hart
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

Review 4.  Allografting for chronic myeloid leukaemia.

Authors:  R A Clift; C Anasetti
Journal:  Baillieres Clin Haematol       Date:  1997-06

5.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

6.  Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.

Authors:  M Nieda; A Nicol; A Kikuchi; K Kashiwase; K Taylor; K Suzuki; K Tadokoro; T Juji
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

7.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.

Authors:  W R Drobyski; C A Keever; M S Roth; S Koethe; G Hanson; P McFadden; J L Gottschall; R C Ash; P van Tuinen; M M Horowitz
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

8.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.

Authors:  D L Porter; M S Roth; C McGarigle; J L Ferrara; J H Antin
Journal:  N Engl J Med       Date:  1994-01-13       Impact factor: 91.245

9.  T-cell immunity to the joining region of p210BCR-ABL protein.

Authors:  W Chen; D J Peace; D K Rovira; S G You; M A Cheever
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

10.  Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins.

Authors:  M Crowley; K Inaba; R M Steinman
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  7 in total

Review 1.  The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases.

Authors:  Changjin Yuan; Guanhua Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2012-05

2.  Defective expression and modulation of B7-2/CD86 on B cells in B cell chronic lymphocytic leukemia.

Authors:  Zhen-sheng Dai; Qin-fen Chen; Hong-zhou Lu; Yi Xie
Journal:  Int J Hematol       Date:  2009-05-09       Impact factor: 2.490

3.  Optimization and limitation of calcium ionophore to generate DCs from acute myeloid leukemic cells.

Authors:  Thanh-Nhan Nguyen Pham; Bo-Hwa Choi; Hyun-Kyu Kang; Chun-Chi Jin; Nguyen Hoang Tuyet Minh; Sang-Ki Kim; Jong-Hee Nam; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Ik-Joo Chung; Je-Jung Lee
Journal:  Cancer Res Treat       Date:  2007-12-31       Impact factor: 4.679

Review 4.  Developing strategies in the immunotherapy of leukemias.

Authors:  Jason B Brayer; Javier Pinilla-Ibarz
Journal:  Cancer Control       Date:  2013-01       Impact factor: 3.302

5.  A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Cheryl L Chiang; Janos Tanyi; Greg Motz; Klara Balint; Rosemarie Mick; George Coukos
Journal:  J Transl Med       Date:  2013-06-18       Impact factor: 5.531

6.  Ca2+/calmodulin-dependent kinase kinase alpha is expressed by monocytic cells and regulates the activation profile.

Authors:  Christopher B Guest; Eric L Deszo; Matthew E Hartman; Jason M York; Keith W Kelley; Gregory G Freund
Journal:  PLoS One       Date:  2008-02-13       Impact factor: 3.240

7.  SjCa8, a calcium-binding protein from Schistosoma japonicum, inhibits cell migration and suppresses nitric oxide release of RAW264.7 macrophages.

Authors:  Ji Liu; Tong Pan; Xu You; Yiyue Xu; Jinyi Liang; Yanin Limpanont; Xi Sun; Kamolnetr Okanurak; Huanqin Zheng; Zhongdao Wu; Zhiyue Lv
Journal:  Parasit Vectors       Date:  2015-10-07       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.